SBIR/STTR Research Award

Transgenic indicator cells for influenza virus

Award identifier 11cd0fd3a33714d4c1b8ffd6b92a0a6d8ebc8fd342008d475cc799e670160261Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$581,898

Program and phase

SBIR · Phase II

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
APATH, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Influenza virus causes a pandemic disease of the respiratory tract that results in significant human morbidity and mortality. Diagnosis of influenza virus infection during the winter months makes up a large component of the clinical virology workload. The goal of this application is to develop transgenic cell lines that facilitate the detection of influenza virus (IV) in clinical specimens. Previously, we developed and patented methods for detecting and quantitating other RNA viruses such as Sindbis virus, a positive-strand RNA virus and respiratory syncytial virus (RSV), a negative-strand RNA virus. The RSV system, while very useful as a research tool, is too complicated in its present format to be useful in a diagnostic test for clinical virology laboratories. Recently, we began working to develop an influenza virus detection system. We constructed a plasmid in which a polymerase I promoter drives transcription of an influenza A virus artificial genomic RNA segment that carries a firefly luciferase gene. Interestingly, we have found that infection of cells transfected with this eDNA exhibited a high level of luciferase whereas uninfected cells expressed background levels. We plan to build on this result and make equivalent influenza B artificial genomic RNA. We will then use these constructs to generate stable cell lines that express a reporter gene only in response to influenza A and/or influenza B virus infection. Such cell lines will form the basis of an influenza detection test which will be developed in Phase II in collaboration with Diagnostic Hybrids, Inc. Athens, OH, and modeled after an existing FDA approved test for herpes simplex virus (ELVIS(r)-HSV).

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.